Welcome to our dedicated page for Trinity Biotech news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech stock.
Trinity Biotech plc reports developments across its commercial-stage diagnostics and health technology business, including clinical laboratory products, point-of-care testing, diabetes management solutions, and wearable biosensor development. Its updates frequently cover the Premier Hb9210 HbA1c laboratory blood glucose monitoring platform, TrinScreen HIV testing, and the CGM+ continuous glucose monitoring program.
Company news also addresses specialty diagnostics initiatives such as EpiCapture prostate cancer testing and autoimmune biomarker work supported by its New York State Department of Health-certified reference laboratory. Other recurring topics include commercial operations in North America, manufacturing and cost-control actions under its Comprehensive Transformation Plan, ADS-based financing arrangements, trading updates, and Nasdaq listing-status notices.
Trinity Biotech (Nasdaq: TRIB) will announce its Q1 2020 financial results on May 27, 2020. A conference call is scheduled for the same day at 11:00 AM ET (4:00 PM BST) to discuss the results. Interested parties can join via a designated dial-in number or access a simultaneous webcast. The replay of the call will be available until June 3, 2020. The company specializes in diagnostic products for both point-of-care and clinical laboratory markets, with global operations in over 75 countries.